The report will be delivered in 2-3 business days.

Antisense & RNAi Therapeutics Market Global Report 2020-30: Covid 19 Growth and Change

Starting Price : $ 4000.00 $3200.00 | Pages : 150 | Published : September 2020 | SKU CODE : 7709 | Format :


The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.

The global antisense &RNAi therapeutics market is expected to decline from $1.14 billion in 2019 to $1.11 billion in 2020 at a compound annual growth rate (CAGR) of -2.89%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.44 billion in 2023 at a CAGR of 9.23%.

North America was the largest region in the antisense & RNAi therapeutics market in 2019. Asia Pacific is expected to be the fastest-growing region in the forecast period.

The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease is the most common neurodegenerative diseases affecting millions of people globally. In the USA, an estimated 930,000 people are expected to have Parkinson’s disease by the end of 2020. Furthermore, according to the World Health Organization (WHO), infectious diseases are a major concern and dominated the WHO’s list of 2019 health threats ranging from various climate change issues to inadequate healthcare facilities. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.

The high cost of RNA interference-based drugs is expected to act as a major restraint for the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Stringent regulations, long product approval process, high development cost, and a comparably small number of patients are few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics’ market growth in upcoming years.

Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2018, Biogen and Ionis announced a collaboration to develop antisense drug candidates for neurological diseases. This collaboration utilizes Biogen’s expertise in neuroscience research and drug development and Ionis’ knowledge in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. The two companies signed an agreement for 10 years.

In November 2019, Novartis International AG, a Switzerland-based pharmaceutical company acquired The Medicines Company, a US-based biopharmaceutical company, for $9.7 million. With the acquisition of The Medicines Company, Novartis International AG plans to enter RNA therapeutics by acquiring its last stage RNA interference drug designed for protection against cardiovascular diseases in twice-yearly shorts. The drug has met the primary endpoint in the three phases of clinical trials and is approved for the treatment of cardiovascular diseases in the USA in 2019 and the EU in early 2020. The Medicines Company is a US-based company focused on the development of RNA drug inclisiran that is used in the treatment of renal impairment and cardiovascular diseases.

The major players covered in the global antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics, Antisense Therapeutics Ltd., Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals), Bio-Path Holdings Inc., Calando Pharmaceuticals, Dicerna Pharmaceuticals, Enzon Pharmaceuticals Inc, Gradalis, iCo Therapeutics, miRagen Therapeutics, Olix Pharmaceuticals, OncoGeneX Pharmaceuticals, Lorus Therapeutics (Aptose Biosciences), Regulus Therapeutics, Rexahn Pharmaceuticals, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Silence Therapeutics Plc, Sirnaomics Inc., Tekmira Pharmaceuticals, Cenix BioScience, Sirnaomics.

The countries covered in the global antisense & RNAi therapeutics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The regions covered in the global antisense & RNAi therapeutics  market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global antisense & RNAi therapeutics market is segmented - 1) By Technology: RNA Interference, Antisense RNA, 2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods, 3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other, .

    1. Executive Summary

    2. Antisense & RNAi Therapeutics Market Characteristics

    3. Antisense & RNAi Therapeutics Market Size And Growth

    3.1. Global Antisense & RNAi Therapeutics Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Antisense & RNAi Therapeutics Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Antisense & RNAi Therapeutics Market Segmentation

    4.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    RNA Interference

    Antisense RNA

    4.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Pulmonary Delivery

    Intravenous Injections

    Intra-dermal Injections

    Intraperitoneal Injections

    Topical Delivery

    Other Delivery Methods

    4.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Oncology

    Cardiovascular Diseases (CVDs)

    Respiratory Disorders

    Neurological Disorders

    Infectious Diseases

    Other

    5. Antisense & RNAi Therapeutics Market Regional And Country Analysis

    5.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Antisense & RNAi Therapeutics Market

    6.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview

    6.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Antisense & RNAi Therapeutics Market

    7.1. China Antisense & RNAi Therapeutics Market Overview

    7.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    7.3. China Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Antisense & RNAi Therapeutics Market

    8.1. India Antisense & RNAi Therapeutics Market Overview

    8.2. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    8.3. India Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Antisense & RNAi Therapeutics Market

    9.1. Japan Antisense & RNAi Therapeutics Market Overview

    9.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9.3. Japan Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Antisense & RNAi Therapeutics Market

    10.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10.2. Australia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Antisense & RNAi Therapeutics Market

    11.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11.2. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Antisense & RNAi Therapeutics Market

    12.1. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Antisense & RNAi Therapeutics Market

    13.1. Western Europe Antisense & RNAi Therapeutics Market Overview

    13.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13.3. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Antisense & RNAi Therapeutics Market

    14.1. UK Antisense & RNAi Therapeutics Market Overview

    14.2. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14.3. UK Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Antisense & RNAi Therapeutics Market

    15.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15.2. Germany Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Antisense & RNAi Therapeutics Market

    16.4. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16.5. France Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Antisense & RNAi Therapeutics Market

    17.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview

    17.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Antisense & RNAi Therapeutics Market

    18.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18.2. Russia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Antisense & RNAi Therapeutics Market

    19.1. North America Antisense & RNAi Therapeutics Market Overview

    19.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19.3. North America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Antisense & RNAi Therapeutics Market

    20.1. USA Antisense & RNAi Therapeutics Market Overview

    20.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20.3. USA Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Antisense & RNAi Therapeutics Market

    21.1. South America Antisense & RNAi Therapeutics Market Overview

    21.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21.3. South America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Antisense & RNAi Therapeutics Market

    22.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22.2. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Antisense & RNAi Therapeutics Market

    23.1. Middle East Antisense & RNAi Therapeutics Market Overview

    23.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23.3. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Antisense & RNAi Therapeutics Market

    24.1. Africa Antisense & RNAi Therapeutics Market Overview

    24.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24.3. Africa Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles

    25.1. Antisense & RNAi Therapeutics Market Competitive Landscape

    25.2. Antisense & RNAi Therapeutics Market Company Profiles

    25.2.1. Alnylam Pharmaceuticals

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Benitec Biopharma Ltd.

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Gene Signal

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. GlaxoSmithKline Plc

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Ionis Pharmaceuticals

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

    27. Antisense & RNAi Therapeutics Market Trends And Strategies

    28. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: China, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: China, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: India, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: India, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: UK, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: UK, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 27: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 28: France, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 29: France, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 31: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 32: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 33: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 34: North America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 35: North America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 36: USA, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 37: USA, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 38: South America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 39: South America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 40: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 41: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 42: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 43: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 44: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 45: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 46: Alnylam Pharmaceuticals Financial Performance
  • Table 47: Benitec Biopharma Ltd. Financial Performance
  • Table 48: Gene Signal Financial Performance
  • Table 49: GlaxoSmithKline Plc Financial Performance
  • Table 50: Ionis Pharmaceuticals Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: China, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: China, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: India, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: India, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: UK, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: UK, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 27: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 28: France, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 29: France, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 31: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 32: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 33: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 34: North America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 35: North America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 36: USA, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 37: USA, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 38: South America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 39: South America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 40: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 41: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 42: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 43: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 44: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 45: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 46: Alnylam Pharmaceuticals Financial Performance
  • Figure 47: Benitec Biopharma Ltd. Financial Performance
  • Figure 48: Gene Signal Financial Performance
  • Figure 49: GlaxoSmithKline Plc Financial Performance
  • Figure 50: Ionis Pharmaceuticals Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)